More than doubled response with IMBRUVICA® + RITUXIMAB1

Secondary Endpoint: Response Rate (RR)1,2

Long-term data from final analysis, with overall follow-up of 63 months; median follow-up of 50 months1,2

  • Response rate was defined as partial response (PR) + very good partial response (VGPR) + complete response (CR)1
  • Observed minor response (MR) rates of 16% in the IMBRUVICA® + rituximab arm and 13% in the rituximab monotherapy arm were not included in the response rate calculation2
    • MR was defined as at least 25% but less than 50% reduction of serum IgM from baseline3
  • Median duration of response with IMBRUVICA® + rituximab was not estimable (range: 1.9+ months, 58.9+ months) after a 63-month follow-up1
  • Median duration of response with placebo + rituximab was not estimable (range: 4.6+ months, 49.7+ months)1

CR=complete response, PR=partial response, RR=response rate, VGPR=very good partial response, WM=Waldenström's macroglobulinemia.

References: 1IMBRUVICA® (ibrutinib) Prescribing Information. 2Buske C, Tedeschi A, Trotman J, et al. Ibrutinib plus rituximab versus placebo plus rituximab for Waldenström's macroglobulinemia: final analysis from the randomized phase III iNNOVATE study. J Clin Oncol. 2022;40(1):52-62. doi:10.1200/JCO.21.00838 3Dimopoulos MA, Tedeschi A, Trotman J, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenstrom's macroglobulinemia. N Engl J Med. 2018;378(25):2399-2410.